Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
Author Information
Author(s): Robinson M K, Hodge K M, Horak E, Sundberg Å L, Russeva M, Shaller C C, von Mehren M, Shchaveleva I, Simmons H H, Marks J D, Adams G P
Primary Institution: Fox Chase Cancer Center
Hypothesis
Co-targeting the preferred ErbB2/ErbB3 heterodimer with a bispecific single-chain Fv (bs-scFv) antibody would promote increased targeting selectivity and induce a therapeutic effect.
Conclusion
The A5-linker-ML3.9 bs-scFv selectively targets ErbB2+/ErbB3+ tumor cells and shows potential as an effective therapeutic agent.
Supporting Evidence
- The A5-linker-ML3.9 bs-scFv showed selective targeting of tumor cells co-expressing ErbB2 and ErbB3.
- ALM treatment inhibited tumor cell growth in vitro.
- ALM demonstrated greater in vivo targeting of ErbB2+/ErbB3+ tumors compared to single-target antibodies.
Takeaway
Scientists created a special antibody that can find and attack cancer cells better by targeting two important markers on the cells at the same time.
Methodology
The study involved constructing and evaluating a bispecific single-chain Fv (bs-scFv) targeting ErbB2 and ErbB3, followed by in vitro and in vivo testing for selectivity and therapeutic effects.
Limitations
The study primarily focused on in vitro and in vivo models, which may not fully replicate human responses.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website